01. Doctor Overview
Dr. Muhammad Furqan is an oncologist at the University of Iowa Hospitals & Clinics (UIHC). He has experience treating esophageal, lung and mesothelioma cancers.
Dr. Furqan has been practicing for more than a decade. He is also the medical director of Clinical Research Services at the Holden Comprehensive Cancer Center at UIHC. This is the only National Cancer Institute (NCI)-designated cancer center in Iowa. The center also specializes in various mesothelioma treatments, including surgeries like extrapleural pneumonectomy.
In addition to practicing medicine, Dr. Furqan is actively involved in academia and research. He received his medical degree in Pakistan at Dow Medical College. He then studied in the United States at Seton Hall University and New York Medical College. Now, he is an associate professor of internal medicine-hematology, oncology, and blood and marrow transplantation.
In 2020, Dr. Furqan received the Cancer Clinical Investigator Team Leadership Award (CCITLA) from the NCI. This award recognizes leadership skills in doctors participating in clinical trials. He has been involved in clinical trials for mesothelioma and lung cancer. Dr. Furqan has also published and co-authored dozens of articles in medical and scientific journals.
02. Fast Facts
Doctor Fast Facts
Main Specialty: Medical Oncology
Other Interests & Specialties: Blood and marrow transplantation, esophageal cancer, experimental therapies, head and neck cancer, hematology, leukemia, lung cancer, lymphoma, mesothelioma, myeloma and pancreatic cancer.
Certifications, Awards & Accolades: American Board of Internal Medicine Certification in Internal Medicine, recipient of a 2020 Cancer Clinical Investigator Team Leadership Award (CCITLA)
Education & Experience:
- Medical Degree from Dow Medical College
- Fellowship in Hematology-Oncology at New York Medical College
- Residency in Internal Medicine at Seton Hall University
Prospective correlation between the patient microbiome with response to and development of immune-mediated adverse effects to immunotherapy in lung cancer. BMC Cancer. July 2021;21(1):808. doi: 10.1186/s12885-021-08530-z
The clinical significance of soluble PD-1 and PD-L1 in lung cancer. Critical Reviews in Oncology/Hematology. November 2019;143:148-152. doi: 10.1016/j.critrevonc.2019.08.009
Comparing high-dose cisplatin with cisplatin-based combination chemotherapy in definitive concurrent chemoradiation setting for locally advanced head and neck squamous cell carcinoma (LAHNSCC). Cancer Medicine. June 2019;8(6):2730-2739. doi: 10.1002/cam4.2139
O 2⋅- and H 2 O 2-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological Ascorbate. Cancer Cell. August 2017;32(2):268. doi: 10.1016/j.ccell.2017.07.008
Once Daily High-dose Radiation (≥60 Gy) Treatment in Limited Stage Small Cell Lung Cancer. Journal of Oncology Translational Research. November 2016;2(1):108.
Germline mutations predisposing to non-small cell lung cancer. Familial Cancer. September 2015;14(3):463-469. doi: 10.1007/s10689-015-9796-x